Cambridge Investment Research Advisors
AVXL icon

Cambridge Investment Research Advisors’s Anavex Life Sciences AVXL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36K Sell
13,960
-1,000
-7% -$2.96K ﹤0.01% 3997
2026
Q1 		$46K Sell
14,960
-7,100
-32% -$30.8K ﹤0.01% 3865
2025
Q4 		$79K Buy
22,060
+955
+5% +$5.85K ﹤0.01% 3724
2025
Q3 		$188K Buy
21,105
+1,102
+6% +$11.2K ﹤0.01% 3498
2025
Q2 		$184K Sell
20,003
-228,136
-92% -$1.95M ﹤0.01% 3365
2025
Q1 		$2.13M Buy
248,139
+164,792
+198% +$1.56M 0.01% 1295
2024
Q4 		$895K Buy
83,347
+63,074
+311% +$485K ﹤0.01% 1963
2024
Q3 		$115K Buy
20,273
+4,000
+25% +$23.1K ﹤0.01% 3247
2024
Q2 		$69K Sell
16,273
-100
-0.6% -$404 ﹤0.01% 3196
2024
Q1 		$83K Buy
16,373
+498
+3% +$2.8K ﹤0.01% 3166
2023
Q4 		$148K Sell
15,875
-400
-2% -$2.75K ﹤0.01% 2972
2023
Q3 		$107K Buy
+16,275
New +$130K ﹤0.01% 2951

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cambridge Investment Research Advisors's AVXL Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Anavex Life Sciences (AVXL) stake by 6.7% in Q2 2026, selling an estimated $2.96K and leaving 13,960 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

Cambridge Investment Research Advisors first reported a position in AVXL in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.13M in Q1 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Cambridge Investment Research Advisors held 13,960 shares of Anavex Life Sciences worth $36K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 1,000 Anavex Life Sciences shares in Q2 2026, an estimated $2.96K.
  • Anavex Life Sciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3997 holding.
  • Cambridge Investment Research Advisors first reported a position in Anavex Life Sciences in Q3 2023 and has held it in 12 quarters since.
  • Cambridge Investment Research Advisors's Anavex Life Sciences position peaked at $2.13M in Q1 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.